AEZS: AEterna Zentaris, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 4:02 PM Aeterna Zentaris (AEZS +1.6%) moves up after posting a better than expected Q1. Zacks upgraded the shares to Outperform from Neutral on the back of the report with a price target of $2.10. Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 7, 7:18 PM Aeterna Zentaris (AEZS): Q1 EPS of $0.07. Revenue of $16.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 17, 12:44 PM AEterna Zentaris (AEZS -2%) says it's agreed to transfer rights and grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA. It will receive a one-time payment of about $3.2M for the transaction, as well as certain other payments to execute a 36-month transitional services agreement to provide various transition services to assist Merck KGaA in assuming responsibility for manufacturing. Comment! [Healthcare, On the Move]
Monday, April 15, 11:30 AM AEterna Zentaris (AEZS -0.6%) appoints David A. Dodd as it's new president and CEO, succeeding Juergen Engel. Dodd was also appointed as a member of the company's board of directors. Comment! [Healthcare]
Thursday, April 11, 9:10 AM Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move]
Wednesday, April 10, 7:51 PM Aeterna Zentaris (AEZS) issues updated proof-of-concept results for its tumor treating Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138. The company says results showed the compounds have high potential for the treatment of luteinizing hormone-releasing hormone receptor positive tumors, particularly in human ovarian and endometrial cancer xenograft models. Shares +19% AH. Comment! [Healthcare, On the Move]
Wednesday, April 10, 6:15 PM After-hours top gainers, as of 5:45 p.m.: AEZS +29%. ZUMZ +10%. PCYG +4%. BLK +4%. MDU +3%.
After-hours top losers: FTNT -15%. APOG -7%. EQIX -4%. FIRE -4%. YUM -3%. Comment! [On the Move]
Wednesday, April 10, 8:39 AM Aeterna Zentaris (AEZS) signs an agreement with Ergomed to carry out Phase III trials of Aeterna's AEZS-108 drug to treat endometrial cancer, the most common gynecologic malignancy. Ergomed will bear 30% of the costs, which are pegged at $30M, and conduct the study, as well as receive a share of any profits. (PR) Comment! [Healthcare]
Thursday, March 21, 5:24 PM More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well revenue. Total sales declined 24% Y/Y, mainly due to the recording of a $2.6M milestone payment from Yakult for the initiation of Phase 1 trials for perifosine in Japan during Q411. Operational expenses declined due to lower employee compensation and benefit costs and a reduced headcount at the drug developer. 2 Comments [Healthcare, Earnings]
Thursday, March 21, 4:24 PM Aeterna Zentaris (AEZS): Q4 EPS of -$0.29. Revenue of $9.5M . (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 11, 12:56 PM Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%. Comment! [On the Move]
Monday, March 11, 12:13 PM Shares of Aetna Zentaris (AEZS) continue to plunge since their resumption of trading, now down 29% at $1.86 after an independent data safety monitoring board recommended discontinuing ongoing Phase 3 studies of perifosine. Comment! [Healthcare, On the Move]
Monday, March 11, 11:47 AM Aeterna Zentaris (AEZS) resumes trading -10%. Comment! [Healthcare, On the Move]
Monday, March 11, 11:33 AM Trading in Aeterna Zentaris (AEZS) will resume at 11:45 AM ET. Comment! [Healthcare]
Monday, March 11, 11:29 AM Shares of Aeterna Zentaris (AEZS -1.9%) remain halted after the company says an independent Data Safety Monitoring Board has recommended discontinuing ongoing Phase 3 studies comparing the efficacy and safety of perifosine in patients with relapsed or relapsed/refractory multiple myeloma. Based on its analysis, the DSMB reported that it was highly unlikely the study would achieve a significant difference in its primary endpoint. Comment! [Healthcare, On the Move]
Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]

AEZS AEterna Zentaris, Inc.

AEZS

AEterna Zentaris, Inc.